Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Freed Website

Eric O. Freed, Ph.D.

Selected Publications

1)  Zhang H, Curreli F, Waheed A, Mercredi P, Mehta M, Bhargava P, Scacalossi D, Tong X, Lee S, Cooper A, Summers M, Freed E, Debnath A.
Dual-acting stapled peptides target both HIV-1 entry and assembly.
Retrovirology. 10: 136, 2013.
Full Text Article. [Journal]
2)  Tedbury P, Ablan S, Freed E.
Global rescue of defects in HIV-1 envelope glycoprotein incorporation: implications for matrix structure.
PLoS Pathog. 9(11): e1003739, 2013.
Full Text Article. [Journal]
3)  Afonin KA, Viard M, Martins AN, Lockett SJ, Maciag AE, Freed EO, Heldman E, Jaeger L, Blumenthal R, Shapiro BA.
Activation of different split functionalities on re-association of RNA-DNA hybrids.
Nat Nanotechnol. 8: 296-304, 2013.
4)  Keren-Kaplan T, Attali I, Estrin M, Kuo LS, Farkash E, Jerabek-Willemsen M, Blutraich N, Artzi S, Peri A, Freed EO, Wolfson HJ, Prag G.
Structure-based in silico identification of ubiquitin-binding domains provides insights into the ALIX-V:ubiquitin complex and retrovirus budding.
EMBO J. 32: 538-51, 2013.
5)  Checkley MA, Luttge BG, Mercredi PY, Kyere SK, Donlan J, Murakami T, Summers MF, Cocklin S, Freed EO.
Reevaluation of the Requirement for TIP47 in Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Incorporation.
J. Virol. 87: 3561-70, 2013.
6)  Van Engelenburg S, Shtengel G, Sengupta P, Waki K, Jarnik M, Ablan S, Freed E, Hess H, Lippincott-Schwartz J.
Distribution of ESCRT machinery at HIV assembly sites reveals virus scaffolding of ESCRT subunits.
Science. 343: 343: 653-656, 2014.
Full Text Article. [Journal]
7)  Freed E, Gale M, eds.
Antiviral Innate Immunity (Part 1).
J Mol Biol. 425: 4857-5044, 2013.
Full Text Article. [Journal (Editor)]
8)  Freed E, Gale M, eds.
Antiviral Innate Immunity (Part 2).
J Mol Biol. 426: 1129-1366, 2014.
Full Text Article. [Journal (Editor)]
9)  Freed E, Gale M.
Antiviral Innate Immunity: Editorial Overview.
J Mol Biol. 426: 1129-1132, 2014.
Full Text Article. [Journal]
10)  Keller PW, Huang RK, England MR, Waki K, Cheng N, Heymann JB, Craven RC, Freed EO, Steven AC.
A Two-Pronged Structural Analysis of Retroviral Maturation Indicates that Core Formation Proceeds by a Disassembly-Reassembly Pathway Rather than a Displacive Transition.
J. Virol. 87: 13655-64, 2013.
11)  Kuo L, Freed E.
HIV-1 assembly cofactors. In: Encyclopedia of AIDS.
Springer; 2013. In Press. [Book Chapter]
12)  Tedbury P, Freed E.
Virus assembly. In: Encyclopedia of AIDS.
Springer; 2013. In Press. [Book Chapter]
13)  Daniels S, Soule E, Davidoff K, Bernbaum J, Hu D, Maeda K, Stahl S, Naiman N, Waheed A, Freed E, Wingfield P, Yarchoan R, Davis D.
Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptide.
FASEB J. 28: 106-116, 2014.
14)  Freed E, eds.
Advances in HIV-1 Assembly and Release.
Switzerland: Springer International Publishing; 2013. [Book (Editor)]
15)  Freed E, Martin M.
Knipe D, Howley P, eds.
HIVs and their replication. In: Fields Virology, 6th Edition. Volume 2.
Philadelphia: Lippincott, Williams, and Wilkins; 2013. p. 1502-1560 [Book Chapter]
16)  Luttge BG, Panchal P, Puri V, Checkley MA, Freed EO.
Mutations in the feline immunodeficiency virus envelope glycoprotein confer resistance to a dominant-negative fragment of Tsg101 by enhancing infectivity and cell-to-cell virus transmission.
Biochim. Biophys. Acta. 1838: 1143-1152, 2014.
Full Text Article. [Journal]
17)  Kuo L, Freed EO.
ARRDC1 as a mediator of microvesicle budding.
Proc. Natl. Acad. Sci. U.S.A. 109: 4025-6, 2012.
18)  Waheed AA, Freed EO.
HIV Type 1 Gag as a Target for Antiviral Therapy.
AIDS Res. Hum. Retroviruses. 28: 54-75, 2012.
19)  Waki K, Durell SR, Soheilian F, Nagashima K, Butler SL, Freed EO.
Structural and Functional Insights into the HIV-1 Maturation Inhibitor Binding Pocket.
PLoS Pathog. 8: e1002997, 2012.
20)  Matreyek KA, Oztop I, Freed EO, Engelman A.
Viral latency and potential eradication of HIV-1.
Expert Rev Anti Infect Ther. 10: 855-7, 2012.
21)  Lu W, Salzwedel K, Wang D, Chakravarty S, Freed E, Wild C, Li F.
A single polymorphism in HIV-1 subtype C SP-1 is sufficient to confer natural resistance to the maturation inhibitor, bevirimat.
Antimicrob Agents Chemother. 55: 3324-9, 2011.
22)  Zhang H, Curreli F, Zhang X, Bhattacharya S, Waheed AA, Cooper A, Cowburn D, Freed EO, Debnath AK.
Antiviral activity of alpha-helical stapled peptides designed from the HIV-1 capsid dimerization domain.
Retrovirology. 8: 28, 2011.
23)  Joshi A, Garg H, Ablan SD, Freed EO.
Evidence of a Role for Soluble N-Ethylmaleimide-sensitive Factor Attachment Protein Receptor (SNARE) Machinery in HIV-1 Assembly and Release.
J. Biol. Chem. 286: 29861-71, 2011.
24)  Checkley MA, Luttge BG, Freed EO.
HIV-1 Envelope Glycoprotein Biosynthesis, Trafficking, and Incorporation.
J. Mol. Biol. 410: 582-608, 2011.
25)  Keller PW, Adamson CS, Heymann JB, Freed EO, Steven AC.
HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice.
J. Virol. 85: 1420-1428, 2011.
Full Text Article. [Journal]
26)  Kim S, Liu F, Im Y, Stephen A, Waheed A, Freed E, Fisher R, Hurley J, Burke T.
Identification of new binding interactions with the tumor susceptibility gene 101 (Tsg101) protein using modified HIV-1 Gag-p6-derived peptide ligands.
ACS Chem Lett. 2: 337-41, 2011.
27)  Balasubramaniam M, Freed EO.
New Insights into HIV Assembly and Trafficking.
Physiology (Bethesda). 26: 236-51, 2011.
28)  Joshi A, Garg H, Ablan S, Freed EO, Nagashima K, Manjunath N, Shankar P.
Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy.
Virology. 415: 95-106, 2011.
29)  Jiang J, Ablan SD, Derebail S, Hercík K, Soheilian F, Thomas JA, Tang S, Hewlett I, Nagashima K, Gorelick RJ, Freed EO, Levin JG.
The interdomain linker region of HIV-1 capsid protein is a critical determinant of proper core assembly and stability.
Virology. 421: 253-65, 2011.
30)  Liu F, Stephen AG, Waheed AA, Freed EO, Fisher RJ, Burke TR.
Application of ring-closing metathesis macrocyclization to the development of Tsg101-binding antagonists.
Bioorg. Med. Chem. Lett. 20: 318-321, 2010.
31)  Im YJ, Kuo L, Ren X, Burgos PV, Zhao XZ, Liu F, Burke TR, Bonifacino JS, Freed EO, Hurley JH.
Crystallographic and Functional Analysis of the ESCRT-I /HIV-1 Gag PTAP Interaction.
Structure. 18: 1536-47, 2010.
32)  Waheed AA, Ablan SD, Sowder RC, Roser JD, Schaffner CP, Chertova E, Freed EO.
Effect of mutations in the human immunodeficiency virus type 1 protease on cleavage of the gp41 cytoplasmic tail.
J Virol. 84: 3121-26, 2010.
33)  Luttge BG, Freed EO.
FIV Gag: Virus assembly and host-cell interactions.
Vet Immunol Immunopathol. 134: 3-13, 2010.
34)  Waki K, Freed EO.
Macrophages and Cell-Cell Spread of HIV-1.
Viruses. 2: 1603-1620, 2010.
35)  Fledderman EL, Fujii K, Ghanam RH, Waki K, Prevelige PE, Freed EO, Saad JS.
Myristate Exposure in the Human Immunodeficiency Virus Type 1 Matrix Protein Is Modulated by pH.
Biochemistry. 49: 9551-9562, 2010.
36)  Adamson CS, Freed EO.
Novel approaches to inhibiting HIV-1 replication.
Antiviral Res. 85: 119-141, 2010.
37)  Adamson C, Sakalian M, Salzwedel K, Freed E.
Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV-1 maturation inhibitor bevirimat.
Retrovirology. 7: 36, 2010.
38)  Freed E, Simon A.
Review of EMBO World Lecture Course 'Virus-host: partners in pathogenesis'.
Future Virol. 5: 379-383, 2010.
39)  Checkley M, Luttge B, Soheilian F, Nagashima K, Freed E.
The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation.
Virology. 400: 137-144, 2010.
40)  Waheed AA, Freed EO.
The Role of Lipids in Retrovirus Replication.
Viruses. 2: 1146-1180, 2010.
41)  Adamson CS, Freed EO.
Anti-HIV-1 Therapeutics: From FDA-approved Drugs to Hypothetical Future Targets.
Mol. Interv. 9: 70-4, 2009.
42)  Joshi A, Nagashima K, Freed EO.
Defects in cellular sorting and retroviral assembly induced by GGA overexpression.
BMC Cell Biol. 10: 72, 2009.
43)  Joshi A, Ablan SD, Soheilian F, Nagashima K, Freed EO.
Evidence that productive human immunodeficiency virus type 1 assembly can occur in an intracellular compartment.
J. Virol. 83: 5375-87, 2009.
44)  Fujii K, Munshi UM, Ablan SD, Demirov DG, Soheilian F, Nagashima K, Stephen AG, Fisher RJ, Freed EO.
Functional role of Alix in HIV-1 replication.
Virology. 391: 284-92, 2009.
45)  Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO.
Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).
J. Virol. 83: 4884-94, 2009.
46)  Bennett AE, Narayan K, Shi D, Hartnell LM, Gousset K, He H, Lowekamp BC, Yoo TS, Bliss D, Freed EO, Subramaniam S.
Ion-abrasion scanning electron microscopy reveals surface-connected tubular conduits in HIV-infected macrophages.
PLoS Pathog. 5: e1000591, 2009.
47)  Waheed AA, Freed EO.
Lipids and membrane microdomains in HIV-1 replication.
Virus Res. 143: 162-76, 2009.
48)  Waheed AA, Ono A, Freed EO.
Methods for the Study of HIV-1 Assembly.
Methods Mol. Biol. 485: 163-84, 2009.
49)  Adamson CS, Salzwedel K, Freed EO.
Virus maturation as a new HIV-1 therapeutic target.
Expert Opin. Ther. Targets. 13: 895-908, 2009.
50)  Joshi A, Munshi U, Ablan SD, Nagashima K, Freed EO.
Functional replacement of a retroviral late domain by ubiquitin fusion.
Traffic. 9: 1972-83, 2008.
51)  Waheed AA, Ablan SD, Soheilian F, Nagashima K, Ono A, Schaffner CP, Freed EO.
Inhibition of human immunodeficiency virus type 1 assembly and release by the cholesterol-binding compound amphotericin B methyl ester: evidence for Vpu dependence.
J. Virol. 82: 9776-81, 2008.
52)  Greene WC, Debyser Z, Ikeda Y, Freed EO, Stephens E, Yonemoto W, Buckheit RW, Esté JA, Cihlar T.
Novel targets for HIV therapy.
Antiviral Res. 80: 251-65, 2008.
53)  Waheed AA, Freed EO.
Peptide inhibitors of HIV-1 egress.
ACS Chem. Biol. 3: 745-7, 2008.
Full Text Article. [Journal]
54)  Zhang H, Zhao Q, Bhattacharya S, Waheed AA, Tong X, Hong A, Heck S, Curreli F, Goger M, Cowburn D, Freed EO, Debnath AK.
A cell-penetrating helical peptide as a potential HIV-1 inhibitor.
J. Mol. Biol. 378: 565-80, 2008.
55)  Joshi A, Garg H, Nagashima K, Bonifacino JS, Freed EO.
GGA and Arf proteins modulate retrovirus assembly and release.
Mol. Cell. 30: 227-38, 2008.
56)  Luttge BG, Shehu-Xhilaga M, Demirov DG, Adamson CS, Soheilian F, Nagashima K, Stephen AG, Fisher RJ, Freed EO.
J Virol. 82: 2106-2119, 2008.
57)  Viard M, Ablan SD, Zhou M, Veenstra TD, Freed EO, Raviv Y, Blumenthal R.
Photoinduced reactivity of the HIV-1 envelope glycoprotein with a membrane-embedded probe reveals insertion of portions of the HIV-1 gp41 cytoplasmic tail into the viral membrane.
Biochemistry. 47: 1977-83, 2008.
58)  Gousset K, Ablan SD, Coren LV, Ono A, Soheilian F, Nagashima K, Ott DE, Freed EO.
Real-time visualization of HIV-1 GAG trafficking in infected macrophages.
PLoS Pathog. 4: e1000015, 2008.
59)  Adamson CS, Freed EO.
Recent progress in antiretrovirals - lessons from resistance.
Drug Discov. Today. 13: 424-32, 2008.
60)  Liu F, Stephen AG, Waheed AA, Aman MJ, Freed EO, Fisher RJ, Burke TR.
SAR by oxime-containing peptide libraries: Application to Tsg101 ligand optimization.
Chembiochem. 9: 2000-4, 2008.
61)  Saad JS, Ablan SD, Ghanam RH, Kim A, Andrews K, Nagashima K, Soheilian F, Freed EO, Summers MF.
Structure of the myristylated human immunodeficiency virus type 2 matrix protein and the role of phosphatidylinositol-(4,5)-bisphosphate in membrane targeting.
J. Mol. Biol. 382: 434-47, 2008.
62)  Freed E, Martin M.
HIVs and their replication. In: Fields Virology, 5th Edition (DM Knipe and PM Howley, eds).
Philadelphia: Lippincott, Williams, and Wilkins; 2007. p. 2107-2186 [Book Chapter]
63)  Tang S, Ablan S, Dueck M, Ayala-López W, Soto B, Caplan M, Nagashima K, Hewlett IK, Freed EO, Levin JG.
A second-site suppressor significantly improves the defective phenotype imposed by mutation of an aromatic residue in the N-terminal domain of the HIV-1 capsid protein.
Virology. 359: 105-15, 2007.
64)  Munshi UM, Kim J, Nagashima K, Hurley JH, Freed EO.
An Alix fragment potently inhibits HIV-1 budding: Characterization of binding to retroviral YPXL late domains.
J. Biol. Chem. 282: 3847-55, 2007.
65)  Fujii K, Hurley JH, Freed EO.
Beyond Tsg101: the role of Alix in 'ESCRTing' HIV-1.
Nat. Rev. Microbiol. 5: 912-6, 2007.
66)  Ono A, Waheed AA, Freed EO.
Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag.
Virology. 360: 27-35, 2007.
67)  Waheed AA, Ablan SD, Roser JD, Sowder RC, Schaffner CP, Chertova E, Freed EO.
HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease.
Proc. Natl. Acad. Sci. U.S.A. 104: 8467-71, 2007.
68)  Joshi A, Freed E.
HIV-1 Gag trafficking.
Future HIV Ther. 1: 427-438, 2007.
Full Text Article. [Journal]
69)  Adamson CS, Freed EO.
Human immunodeficiency virus type 1 assembly, release, and maturation.
Adv. Pharmacol. 55: 347-87, 2007.
70)  Waheed AA, Freed EO.
Influenza virus not cRAFTy enough to dodge viperin.
Cell Host Microbe. 2: 71-2, 2007.
71)  Saad JS, Loeliger E, Luncsford P, Liriano M, Tai J, Kim A, Miller J, Joshi A, Freed EO, Summers MF.
Point mutations in the HIV-1 matrix protein turn off the myristyl switch.
J. Mol. Biol. 366: 574-85, 2007.
72)  Garg H, Joshi A, Freed EO, Blumenthal R.
Site-specific Mutations in HIV-1 gp41 Reveal a Correlation between HIV-1-mediated Bystander Apoptosis and Fusion/Hemifusion.
J. Biol. Chem. 282: 16899-906, 2007.
73)  Lee S, Joshi A, Nagashima K, Freed EO, Hurley JH.
Structural basis for viral late-domain binding to Alix.
Nat. Struct. Mol. Biol. 14: 194-9, 2007.
74)  Davis MR, Jiang J, Zhou J, Freed EO, Aiken C.
A Mutation in the Human Immunodeficiency Virus Type 1 Gag Protein Destabilizes the Interaction of the Envelope Protein Subunits gp120 and gp41.
J Virol. 80: 2405-17, 2006.
75)  Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, Yunus AS, Adamson CS, Salzwedel K, Martin DE, Allaway GP, Freed EO, Wild CT.
Determinants of activity of the HIV-1 maturation inhibitor PA-457.
Virology. 356: 217-24, 2006.
76)  Fu W, Dang Q, Nagashima K, Freed EO, Pathak VK, Hu WS.
Effects of Gag mutation and processing on retroviral dimeric RNA maturation.
J Virol. 80: 1242-9, 2006.
77)  Freed EO.
HIV-1 Gag: Flipped out for PI(4,5)P2.
Proc. Natl. Acad. Sci. U.S.A. 103: 11101-2, 2006.
78)  Liu F, Stephen AG, Adamson CS, Gousset K, Aman MJ, Freed EO, Fisher RJ, Burke TR.
Hydrazone- and hydrazide-containing N-substituted glycines as peptoid surrogates for expedited library synthesis: application to the preparation of Tsg101-directed HIV-1 budding antagonists.
Org. Lett. 8: 5165-8, 2006.
79)  Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO.
In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).
J. Virol. 80: 10957-71, 2006.
80)  Waheed AA, Ablan SD, Mankowski MK, Cummins JE, Ptak RG, Schaffner CP, Freed EO.
Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants.
J. Biol. Chem. 281: 28699-711, 2006.
81)  Joshi A, Nagashima K, Freed EO.
Mutation of dileucine-like motifs in the human immunodeficiency virus type 1 capsid disrupts virus assembly, gag-gag interactions, gag-membrane binding, and virion maturation.
J. Virol. 80: 7939-51, 2006.
82)  Freed EO, Mouland AJ.
The cell biology of HIV-1 and other retroviruses.
Retrovirology. 3: 77, 2006.
83)  Ono A, Waheed AA, Joshi A, Freed EO.
Association of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay.
J Virol. 79: 14131-40, 2005.
84)  Sklar PA, Masur H, Grubb JR, Voell J, Witek J, Ono A, Freed EO, Maldarelli F.
Pravastin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy.
AIDS. 19: 1109-1111, 2005.
85)  Ono A, Freed EO.
Role of lipid rafts in virus replication.
Adv. Virus Res. 64: 311-58, 2005.
86)  Ono A, Freed EO.
Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body.
J Virol. 78: 1552-63, 2004.
87)  Freed EO.
HIV-1 and the host cell: An intimate association.
Trends Microbiol. 12: 170-177, 2004.
88)  Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, Ono A, Freed EO, Hu WS, Pathak VK.
Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
J Biol Chem. 279: 35822-8, 2004.
89)  Shehu-Xhilaga M, Ablan S, Demirov DG, Chen C, Montelaro RC, Freed EO.
Late domain-dependent inhibition of equine infectious anemia virus budding.
J Virol. 78: 724-32, 2004.
90)  Freed EO, eds.
Mechanisms of Enveloped Virus Release.
Virus Res. 106: ., 2004.
[Journal (Editor)]
91)  Ono A, Ablan SD, Lockett SJ, Nagashima K, Freed EO.
Phosphatidylinositol (4,5) bisphosphate regulates HIV-1 Gag targeting to the plasma membrane.
Proc Natl Acad Sci U S A. 101: 14889-94, 2004.
92)  Freed EO.
Preface in Mechanisms of Enveloped Virus Release.
Virus Res. 106: 85-6, 2004.
93)  Murakami T, Ablan S, Freed EO, Tanaka Y.
Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity.
J Virol. 78: 1026-31, 2004.
94)  Demirov DG, Freed EO.
Retrovirus budding in Mechanisms of Enveloped Virus Release.
Virus Res. 106: 87-102, 2004.
95)  Freed EO, Ross SR.
Retroviruses 2004: Review of the 2004 Cold Spring Harbor Retroviruses conference.
Retrovirology. 1: 25, 2004.
96)  Goila-Gaur R, Demirov DG, Orenstein JM, Ono A, Freed EO.
Defects in human immunodeficiency virus budding and endosomal sorting induced by TSG101 overexpression.
J Virol. 77: 6507-19, 2003.
97)  Tang S, Murakami T, Cheng N, Steven AC, Freed EO, Levin JG.
Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase.
J Virol. 77: 12592-602, 2003.
98)  Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT.
PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.
Proc Natl Acad Sci U S A. 100: 13555-60, 2003.
99)  Freed EO.
The HIV-TSG101 interface: recent advances in a budding field.
Trends Microbiol. 11: 56-9, 2003.
100)  Farr SA, Banks WA, Uezu K, Freed EO, Kumar VB, Morley JE.
Mechanisms of HIV type 1-induced cognitive impairment: evidence for hippocampal cholinergic involvement with overstimulation of the VIPergic system by the viral coat protein core.
AIDS Res Hum Retroviruses. 18: 1189-95, 2002.
101)  Demirov DG, Ono A, Orenstein JM, Freed EO.
Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function.
Proc Natl Acad Sci U S A. 99: 955-60, 2002.
102)  Demirov DG, Orenstein JM, Freed EO.
The late domain of human immunodeficiency virus type 1 p6 promotes virus release in a cell type-dependent manner.
J Virol. 76: 105-17, 2002.
103)  Freed EO.
Viral late domains.
J Virol. 76: 4679-87, 2002.
104)  Freed EO.
Virology. Rafting with Ebola.
Science. 296: 279, 2002.
105)  Freed EO.
HIV-1 replication.
Somat Cell Mol Genet. 26: 13-33, 2001.
106)  Freed EO, Martin MA.
HIVs and their replication.
In Fields Virology. Chapter 59, 4th Ed (Knipe DM and Howley PM, eds): 1971-2041, 2001.
107)  Tang S, Murakami T, Agresta BE, Campbell S, Freed EO, Levin JG.
Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells.
J Virol. 75: 9357-66, 2001.
108)  Ono A, Freed EO.
Plasma membrane rafts play a critical role in HIV-1 assembly and release.
Proc Natl Acad Sci U S A. 98: 13925-30, 2001.
109)  Banks WA, Freed EO, Wolf KM, Robinson SM, Franko M, Kumar VB.
Transport of human immunodeficiency virus type 1 pseudoviruses across the blood-brain barrier: role of envelope proteins and adsorptive endocytosis.
J Virol. 75: 4681-91, 2001.
110)  Murakami T, Freed EO.
Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail.
J Virol. 74: 3548-54, 2000.
111)  Ono A, Demirov D, Freed EO.
Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding.
J Virol. 74: 5142-50, 2000.
112)  Ono A, Orenstein JM, Freed EO.
Role of the Gag matrix domain in targeting human immunodeficiency virus type 1 assembly.
J Virol. 74: 2855-66, 2000.
113)  Murakami T, Freed EO.
The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.
Proc Natl Acad Sci U S A. 97: 343-8, 2000.
114)  Halvas EK, Svarovskaia ES, Freed EO, Pathak VK.
Wild-type and YMDD mutant murine leukemia virus reverse transcriptases are resistant to 2',3'-dideoxy-3'-thiacytidine.
J Virol. 74: 6669-74, 2000.
Click Here to View Collapsed Bibliography.

This page was last updated on 3/4/2014.